Cysticercosis in Emergency Medicine 

  • Author: Ryan Tenzer, MD, FAAEM; Chief Editor: Barry E Brenner, MD, PhD, FACEP   more...
 
Updated: Apr 28, 2009
 

Background

Cysticercosis is a systemic illness caused by dissemination of the larval form of the pork tapeworm, Taenia solium. Encystment of larvae can occur in almost any tissue. Involvement of the central nervous system (CNS), known as neurocysticercosis (NCC), is the most clinically important manifestation of the disease and may present with dramatic findings. Neurocysticercosis is a major cause of seizure disorder in parts of the developing world and its incidence is increasing within developed countries.

Nonenhanced (left) and enhanced (right) CT scans oNonenhanced (left) and enhanced (right) CT scans of the brain in a patient with neurocysticercosis show multiple ring-enhancing lesions with perifocal edema.
Next

Pathophysiology

Humans are the definitive T solium hosts and can carry an intestinal adult tapeworm (taeniasis), often without symptoms. Intermittent fecal shedding of egg-containing proglottids or free T solium eggs ensues, with the intention that the intermediate host (normally pigs) will ingest the excreted eggs in contaminated food or water. T solium embryos penetrate the GI mucosa of the pig and are hematogenously disseminated to peripheral tissues with resultant formation of larval cysts (cysticerci). When undercooked pork is consumed, an intestinal tapeworm will again be formed, completing the life cycle of the worm.

Human cysticercosis occurs when T solium eggs are ingested via fecal-oral transmission from a tapeworm host. The human then becomes an accidental intermediate host, with development of cysticerci within organs. Cysticerci may be found in almost any tissue. The most frequently reported locations are skin, skeletal muscle, heart, eye, and the central nervous system (CNS). Involvement of the CNS leads to the most important manifestation of the disease, neurocysticercosis (NCC).

Symptomatology of neurocysticercosis (NCC) is largely dependent on the presence of pericystic inflammation, the absence of which will usually manifest as asymptomatic disease. Lack of perilesional inflammation is seen with both "active" healthy parasites, which are able to evade host immunity (an adaptive feat that may be abetted by the immune privilege afforded to the CNS), and in "inactive" disease in which the cysticerci have completely involuted. As a corollary, inflammation is restricted to currently live but degenerating cysts whose ability to escape host defenses is faltering. Upon imaging, these inflamed degenerating cysts are typically seen as ring-enhancing lesions, an appearance that may be termed colloidal. Eventually, cysts will involute and either vanish or undergo granulomatous change and exhibit calcific scarring. Cysts in various stages of viability can be seen simultaneously in one host.

In patients with advanced HIV disease and compromised cell-mediated immunity, neurocysticercosis may is exist without significant host response and is likely to be asymptomatic. For this reason, in symptomatic patients with CD4 counts under 200 cells/mm3, alternative diagnoses should be considered.[1]

Serious pathologic findings of neurocysticercosis (NCC) can include seizures, encephalopathy, obstructive hydrocephalus, meningoencephalitis, and vascular accidents. Involvement of brain parenchyma is common and leads to the most frequent presentation of seizure or headache. Clinical expression of NCC depends primarily on the number and location of CNS cysticerci and degree of inflammatory response. As previously mentioned, host immune response and resultant pericystic inflammation are considered largely responsible for parenchymal disease manifestations. However, some evidence indicates that involuted calcific lesions may be epileptogenic as well and thus contribute to significant morbidity.

Extraparenchymal ventricular and subarachnoid cysts also are found. These carry a worse prognosis and often lead to obstructing hydrocephalus requiring surgical intervention. Cysticerci within the basilar cisterns or Sylvian fissures may become quite large. Those within the cisterns may also cause vasculitis and stroke. Spinal NCC is rare.

Ocular cysts are mostly vitreous, but they may be found in subretinal locations. Visualization of cysts via funduscopy may be diagnostic of the disease. Subcutaneous nodules represent cysticerci in the skin. Skeletal muscle encystment usually is asymptomatic but may cause muscular pseudohypertrophy with a heavy parasite burden. Cardiac cysts may lead to conduction system abnormalities.

Previous
Next

Epidemiology

Frequency

United States

Incidence in the United States is increasing due to increased immigration from and travel to endemic areas and improved serologic testing and availability of diagnostic imaging. An estimated 1000 new cases are diagnosed per year in the United States. In southern California, with its large population of immigrants, neurocysticercosis (NCC) may account for at least 10% of seizures seen in some emergency departments and more than 2% of neurological or neurosurgical admissions.[2] The diagnosis of NCC should be considered in any patient from an endemic area presenting with new-onset seizures.

International

Cysticercosis affects an estimated 50 million people worldwide. Endemic areas include Mexico and Latin America, sub-Saharan Africa, India, and East Asia. NCC is a leading cause of adult-onset seizures worldwide.

Mortality/Morbidity

Morbidity may result from seizures, strokes, or hydrocephalus and from effects of long-term treatment with anticonvulsants, steroids, or cerebrospinal fluid shunts.

Mortality from cysticercosis is minimal and generally limited to cases complicated by encephalitis, cerebral edema, hydrocephalus and stroke.

Race

Hispanic and Asian populations are more commonly affected due to immigration patterns from endemic areas. The disease is prevalent in South Asia as well, where patients more commonly present with a solitary cyst.

Age

People of any age may be affected. Children may be more likely to develop an unusual encephalitis-type variant.

Previous
 
 
Contributor Information and Disclosures
Author

Ryan Tenzer, MD, FAAEM  Clinical Assistant Professor of Emergency Medicine, Penn State College of Medicine; Consulting Staff, Department of Emergency Medicine, Lehigh Valley Hospital

Ryan Tenzer, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians

Disclosure: Nothing to disclose.

Coauthor(s)

Howard A Blumstein, MD, FAAEM  Assistant Professor, Surgery; Medical Director, Department of Emergency Medicine, Wake Forest University School of Medicine

Howard A Blumstein, MD, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, Emergency Medicine Residents Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

William K Chiang, MD  Associate Professor, Department of Emergency Medicine, New York University School of Medicine; Chief of Service, Department of Emergency Medicine, Bellevue Hospital Center

William K Chiang, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Barry J Sheridan, DO  Chief Warrior in Transition Services, Brooke Army Medical Center

Barry J Sheridan, DO is a member of the following medical societies: American Academy of Emergency Medicine

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Barry E Brenner, MD, PhD, FACEP  Professor of Emergency Medicine, Professor of Internal Medicine, Program Director, Emergency Medicine, Case Medical Center, University Hospitals, Case Western Reserve University School of Medicine

Barry E Brenner, MD, PhD, FACEP is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Chest Physicians, American College of Emergency Physicians, American College of Physicians, American Heart Association, American Thoracic Society, Arkansas Medical Society, New York Academy of Medicine, New York Academy of Sciences, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

References
  1. Prasad S, MacGregor RR, Tebas P. Management of potential neurocysticercosis in patients with HIV infection. Clin Infect Dis. Feb 15 2006;42(4):e30-4. [Medline].

  2. Ong S, Talan DA, Moran GJ. Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments. Emerg Infect Dis. Jun 2002;8(6):608-13. [Medline].

  3. Kramer LD, Locke GE, Byrd SE. Cerebral cysticercosis: documentation of natural history with CT. Radiology. May 1989;171(2):459-62. [Medline].

  4. Das K, Mondal GP, Banerjee M, Mukherjee BB, Singh OP. Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. J Clin Neurosci. Dec 2007;14(12):1172-7. [Medline].

  5. [Best Evidence] Del Brutto OH, Roos KL, Coffey CS, Garcia HH. Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med. Jul 4 2006;145(1):43-51. [Medline].

  6. Salinas R, Counsell C, Prasad K. Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. Trop Med Int Health. Nov 1999;4(11):713-8. [Medline].

  7. [Best Evidence] Gongora-Rivera F, Soto-Hernandez JL, Gonzalez Esquivel D, Cook HJ, Marquez-Caraveo C, Hernandez Davila R, et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology. Feb 14 2006;66(3):436-8. [Medline].

  8. Botero D, Tanowitz HB, Weiss LM, Wittner M. Taeniasis and cysticercosis. Infect Dis Clin North Am. Sep 1993;7(3):683-97. [Medline].

  9. Buitrago M, Edwards B, Rosner F. Neurocysticercosis: Report of fifteen cases. Mt Sinai J Med. Nov 1995;62(6):439-44. [Medline].

  10. [Best Evidence] Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews H. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. Sep 2008;79(9):1050-5. [Medline].

  11. Del Brutto OH. Cysticercosis and cerebrovascular disease: a review. J Neurol Neurosurg Psychiatry. Apr 1992;55(4):252-4. [Medline].

  12. Del Brutto OH, Rajshekhar V, White AC. Proposed diagnostic criteria for neurocysticercosis. Neurology. Jul 24 2001;57(2):177-83. [Medline].

  13. Garcia HH, Del Brutto OH. Imaging findings in neurocysticercosis. Acta Trop. Jun 2003;87(1):71-8. [Medline].

  14. Garcia HH, Del Brutto OH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol. Oct 2005;4(10):653-61. [Medline].

  15. Garcia HH, Pretell EJ, Gilman RH. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med. Jan 15 2004;350(3):249-58. [Medline].

  16. Kalra V, Dua T, Kumar V. Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. J Pediatr. Jul 2003;143(1):111-4. [Medline].

  17. Lamont EB, Sayah A. An occult cause of persistent nausea and vomiting. J Emerg Med. Sep-Oct 1997;15(5):633-5. [Medline].

  18. Loyo-Varela M. Surgical treatment of cerebral cysticercosis. Eur Neurol. 1997;37(2):129-30. [Medline].

  19. Mitchell WG. Pediatric neurocysticercosis in North America. Eur Neurol. 1997;37(2):126-9. [Medline].

  20. Mitchell WG, Crawford TO. Intraparenchymal cerebral cysticercosis in children: diagnosis and treatment. Pediatrics. Jul 1988;82(1):76-82. [Medline].

  21. Richards F Jr, Schantz PM. Laboratory diagnosis of cysticercosis. Clin Lab Med. Dec 1991;11(4):1011-28. [Medline].

  22. Rosenfeld EA, Byrd SE, Shulman ST. Neurocysticercosis among children in Chicago. Clin Infect Dis. Aug 1996;23(2):262-8. [Medline].

  23. Salgado P, Rojas R, Sotelo J. Cysticercosis. Clinical classification based on imaging studies. Arch Intern Med. Sep 22 1997;157(17):1991-7. [Medline].

  24. Sciutto E, Chavarria A, Fragoso G, Fleury A, Larralde C. The immune response in Taenia solium cysticercosis: protection and injury. Parasite Immunol. Dec 2007;29(12):621-36. [Medline].

  25. White AC Jr. Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis. Feb 1997;24(2):101-13; quiz 114-5. [Medline].

  26. White AC Jr. Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management. Annu Rev Med. 2000;51:187-206. [Medline].

Previous
Next
 
Nonenhanced CT scan of the brain demonstrates the multiple calcified lesions of inactive parenchymal neurocysticercosis.
Enhanced CT scan of the brain in a patient with neurocysticercosis demonstrates a live cyst with a minimally enhancing wall and an eccentric hyperattenuating scolex.
Nonenhanced (left) and enhanced (right) CT scans of the brain in a patient with neurocysticercosis show multiple ring-enhancing lesions with perifocal edema.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.